science

Cosmetic regulation 2026: EU vs US FDA, what the gap means for you

SkinScore Editorial | |Updated on
cosmetic regulationEU vs USFDAMoCRAEC 1223 2009safety2026
Two skincare bottles side by side on a neutral background suggesting a regulatory comparison between the EU and the US

Walk into a Sephora in Paris and one in New York and you can buy the same brand names, yet the formulas behind those labels sometimes differ. The reason sits in two regulatory systems that agree on the big picture and disagree on the details. Understanding the EU versus US cosmetic regulation gap changes how you read an INCI list, how you interpret marketing claims and how you spot a real difference between two versions of the same serum.

TL;DR: The EU uses Regulation 1223/2009 with a pre-market safety file, about 1700 banned or restricted ingredients and ANSM cosmetovigilance. The US uses the FD&C Act updated by MoCRA (fully in force in 2024) with federal facility registration, product listing and adverse event reporting, and a much shorter federal ban list. Sunscreen filter approval is where the two systems diverge most in cosmetic regulation 2026. Neither system is unsafe. They just draw the line at different places, and the difference explains most of the formula gap between EU and US versions of the same skincare product.

What Changed in 2026 Cosmetic Regulation

Two structural updates matter for the 2026 landscape. In the EU, the ongoing revision of Regulation 1223/2009 has continued the migration of endocrine disruptor rules from CMR (carcinogenic, mutagenic, reprotoxic) provisions into cosmetic annexes, along with tightened rules on nanomaterials and on allergens disclosure. The number of individually declarable fragrance allergens has grown to more than 80, up from the historical 26.

In the US, the Modernization of Cosmetics Regulation Act (MoCRA) came fully into force in late 2024, and 2026 is the first full calendar year with all its requirements operational. Facility registration, product listing, mandatory adverse event reporting, records access for the FDA and Good Manufacturing Practice alignment are now federal obligations, not voluntary practices.

The consequence is that the two systems have moved closer in structure while still differing sharply in the details, and this is exactly why comparing them ingredient by ingredient still shows a real gap.

How the EU Regulates Cosmetics: Regulation 1223/2009

The EU framework rests on a single text applicable across all 27 member states: Regulation (EC) No 1223/2009. Before a cosmetic product reaches the market, a Responsible Person, a legal entity established in the EU, must compile a Product Information File (PIF) that includes the Cosmetic Product Safety Report (CPSR).

The CPSR is not paperwork. It contains toxicological profiles for every ingredient, exposure calculations, margin of safety values, stability data, microbiological quality data and use conditions. A qualified safety assessor signs it. The Responsible Person is legally accountable for keeping the file up to date and available to national authorities.

At the ingredient level, four annexes carry the operational rules. Annex II lists prohibited ingredients (currently around 1700 entries). Annex III lists restricted ingredients with concentration limits and use conditions. Annex IV, V and VI list the only permitted colorants, preservatives and UV filters respectively. That last point is central: if a UV filter is not on Annex VI, it cannot be sold in a European sunscreen, full stop.

The Scientific Committee on Consumer Safety issues formal opinions on any ingredient the European Commission asks it to review. In France, ANSM enforces the regulation, runs cosmetovigilance and can order a product off shelves. The Haute Autorite de Sante and Inserm contribute broader public health syntheses that feed into national dermatology guidance.

How the US Regulates Cosmetics: MoCRA and the FDA

In the US, cosmetics fall under the Federal Food, Drug and Cosmetic Act (FD&C Act) enforced by the FDA. Historically the FDA had limited pre-market authority over cosmetics, which is the origin of the "less regulated" reputation, but that description is now outdated.

The Modernization of Cosmetics Regulation Act (MoCRA), passed in December 2022 and fully in force by late 2024, gives the FDA the largest expansion of cosmetic authority in more than 80 years. Manufacturers must register their facilities, list every product with its ingredients, report serious adverse events within 15 business days, keep safety substantiation records, comply with GMP once the rulemaking is finalised, and follow labelling rules for professional-use products and fragrance allergens.

The FDA works with the Cosmetic Ingredient Review (CIR) expert panel for ingredient safety assessments. CIR reports are published, peer-reviewed and used by industry and regulators alike. The FDA can also refer to National Toxicology Program (NTP) evaluations and to the peer-reviewed toxicology literature indexed on PubMed.

The gap that remains is not about accountability. It is about the shape of the list of prohibited ingredients, and about the sunscreen category, which is regulated as an over-the-counter drug in the US and as a cosmetic in the EU.

Ingredient Bans: The Real Number Gap

The "EU bans 1700 ingredients, US bans 11" line is a favourite of clean beauty marketing. It is technically true and profoundly misleading. Comparing counts across two different legal architectures without adjusting for scope tells you very little about actual product safety.

Three points reframe the number.

First, most of the 1700 EU entries are substances that were never used in cosmetics or that were banned decades ago (dye intermediates, industrial solvents, heavy metal salts). Their absence from a US ban list does not mean they are legally permitted in a US cosmetic. The FDA can act under general adulteration provisions if a substance renders a cosmetic injurious to health.

Second, the US framework relies more heavily on self-regulation through CIR opinions and industry safety substantiation, backed by post-market authority. If the CIR concludes an ingredient is unsafe under stated conditions, US brands generally do not use it, even in the absence of a specific federal ban.

Third, the practical formulation gap between an EU and a US version of the same product usually comes from a handful of well-known differences: sunscreen filters, some preservatives, some hair dye intermediates, some CMR-classified compounds and specific fragrance allergens. Our EWG Skin Deep critique covers how hazard-only counts get weaponised in marketing.

Sunscreens: Where the Two Systems Diverge Most

Sunscreens are the single most visible regulatory gap. In the EU, sunscreens are cosmetics regulated under Annex VI of Regulation 1223/2009. New UV filters can be evaluated by the SCCS and added to the annex when they clear the risk assessment. This is why filters such as bemotrizinol, bisoctrizole and Tinosorb S have been available in European sunscreens for two decades.

In the US, sunscreen actives are over-the-counter drugs. New filters need to pass the FDA's TEA (Time and Extent Application) or a full NDA (New Drug Application) pathway, which has proved slow. As a result, the US filter list has effectively been frozen since the 1990s for organic filters, with progress only on zinc oxide and titanium dioxide on the mineral side.

For a full comparison of the two filter lists, see our detailed post on EU versus US sunscreen filters. The practical impact is that a EU sunscreen can offer broader UVA coverage at lighter textures, while a US sunscreen often has to rely on higher SPF numbers to reach comparable protection. Our guide to chemical versus mineral sunscreen covers the format trade-offs.

The American Academy of Dermatology and the European Academy of Dermatology and Venereology both continue to recommend daily broad-spectrum photoprotection as one of the highest evidence interventions against photoaging and non-melanoma skin cancer.

Preservatives, Fragrance and Allergens

Preservatives are the second most visible category where the two systems diverge in practice. The EU Annex V lists the only permitted preservatives, each with a concentration cap and use conditions. Phenoxyethanol is limited to 1 percent and restricted in leave-on products for children under three. Parabens are capped, with several longer chain versions prohibited. Methylisothiazolinone is banned in leave-on products.

The US relies more on CIR opinions and manufacturer safety substantiation. Most of the preservatives permitted in the EU are also used in the US, at concentrations aligned with the same CIR recommendations. The formal legal architecture differs, but the day to day formulation choices converge. See our full review of the paraben safety evidence for the SCCS 2020 and 2023 opinions.

Fragrance rules diverge more sharply. The EU requires individual disclosure of more than 80 fragrance allergens above defined concentration thresholds. The US requires disclosure of specific allergens only for professional-use products under MoCRA, with rulemaking still pending for retail products at the time of writing. This affects labelling more than composition, but if you have documented contact dermatitis it is a real difference. Our post on fragrance free versus unscented labelling explains what those terms actually mean.

Cosmetic Claims: Efficacy vs Marketing Language

Both systems limit the claims a cosmetic can make. In the EU, Regulation 655/2013 sets six common criteria: legal compliance, truthfulness, evidential support, honesty, fairness and informed decision making. A brand claiming "reduces wrinkles by 30 percent" must have data to back it.

In the US, the FDA distinguishes cosmetic claims from drug claims. A cosmetic can claim to cleanse, beautify, promote attractiveness or alter appearance. Anything that suggests treating, preventing or diagnosing a disease crosses into drug territory and requires a New Drug Application. This is why acne treatments, sunscreens and antiperspirants are OTC drugs in the US, while in the EU they are cosmetics with claim substantiation.

The practical consequence: a French anti-acne serum with salicylic acid is a cosmetic, a US anti-acne serum with the same 2 percent salicylic acid is an OTC drug with a Drug Facts panel. Same molecule, same concentration, different legal box. Reading the INCI list tells you what is inside, regulatory status tells you the legal frame around it.

Cosmetovigilance and Post-Market Surveillance

Both systems now run active post-market surveillance, and this is where MoCRA has closed the biggest gap.

In the EU, cosmetovigilance is mandatory. Serious undesirable effects (SUE) must be reported by the Responsible Person to the national authority (ANSM in France) without delay. ANSM aggregates signals, can trigger risk assessments and can order recalls. National dermatology networks contribute to signal generation. Inserm and HAS integrate cosmetovigilance data into broader environmental health syntheses.

In the US, MoCRA now mandates adverse event reporting within 15 business days for serious adverse events, with records to be kept for six years. The FDA can inspect records, order mandatory recalls and require label warnings. Prior to MoCRA these powers were largely voluntary. That is the single biggest 2024 change in the US framework, and it directly reduces the historical gap with the EU on post-market authority.

What This Means for Your Shopping Cart

For everyday routines, three practical takeaways matter more than the regulatory theory.

  1. Do not read a "clean beauty" list as a regulatory verdict. A retailer banning 1500 ingredients is a marketing choice, not a safety statement. Our clean beauty analysis unpacks the incentive structure.
  2. Sunscreen is the one category where the EU version really is often technically ahead. If you travel or shop online, an EU sunscreen with modern filters may give lighter texture at comparable UVA protection. Both AAD and EADV recommend daily use whatever the filter list.
  3. Read your INCI list against the actual formula, not a hazard app. Percentages, product category, residence time and your own skin history matter more than any single ingredient flag.

For readers building or rebuilding a routine, our evidence based acne routine and rosacea routine posts walk through the decision process with regulatory status and clinical evidence in mind.

FAQ

Is the EU really stricter than the US on cosmetics?

It depends on the metric. The EU has a longer prohibited ingredient list and a formal pre-market safety file. The US, since MoCRA came fully into force in 2024, now has mandatory facility registration, adverse event reporting and recall authority. On sunscreen filters the EU list is broader, on labelling of fragrance allergens the EU is more demanding.

Does the FDA test cosmetics before they hit the market?

No. Neither does any EU authority. Both systems rely on the manufacturer to substantiate safety before market entry, with the difference that the EU requires a formal CPSR signed by a qualified assessor. Regulators intervene mostly post-market through inspections, cosmetovigilance and recalls.

Why can I buy sunscreen filters in France that are not available in the US?

Because in the EU sunscreens are cosmetics regulated under Annex VI of 1223/2009, while in the US they are OTC drugs requiring FDA approval of each active. The FDA approval pathway for new sunscreen filters has been effectively stalled for organic filters since the 1990s.

Not exactly. The EU caps methylparaben and ethylparaben at defined concentrations and has prohibited several longer chain parabens (isopropylparaben, isobutylparaben, phenylparaben, benzylparaben, pentylparaben). The US permits parabens with CIR support. Both frameworks agree on the safety of methylparaben and ethylparaben at cosmetic concentrations.

What is MoCRA and does it change what I can buy in 2026?

MoCRA is the Modernization of Cosmetics Regulation Act, in force since late 2024. It requires facility registration, product listing, adverse event reporting, safety substantiation records and GMP compliance. For consumers, the visible change is mostly on labelling of professional-use fragrance allergens and on the recall infrastructure. It does not radically alter the ingredient list you see on shelves.

Do dermatologists prefer EU or US formulas?

Board-certified dermatologists in both regions follow clinical evidence more than regulatory geography. The AAD, EADV, ANSM, HAS and Inserm publish guidance that converges on the major questions (photoprotection, retinoids, barrier care, acne). The regulatory choice matters mostly at the margin, and mostly for sunscreens and for specific allergen sensitivities.

How can I check the regulatory status of a specific ingredient?

For the EU, the CosIng database on the European Commission website lists status, restrictions and SCCS opinions. For the US, the FDA cosmetics section and the CIR reports database are the reference sources. Both are free and searchable. Peer-reviewed literature on PubMed adds the primary science behind the opinions.

Sources and Further Reading

Enjoyed this? Share it